Fig. 6: Lenvatinib leads to a partial response after progression to pemigatinib in the presence of the N549K resistance-mediating mutation. | Nature Communications

Fig. 6: Lenvatinib leads to a partial response after progression to pemigatinib in the presence of the N549K resistance-mediating mutation.

From: The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Fig. 6

Axial contrast-enhanced CT of the liver in the portal-venous phase after progressive disease to pemigatinib in the presence of an N549K kinase mutation detected in a liver biopsy of a progressive lesion. From left to right: progressive disease during therapy with pemigatinib; baseline CT scan prior to lenvatinib; first follow-up scan 29 days later with consistent shrinkage of all liver lesions, accompanied by considerable reductions of the rim enhancement; second follow-up 89 days after the start of lenvatinib, showing a confirmation of the treatment responses with even more efficient reduction of tumor manifestations, some of them having completely disappeared; further confirmation of the ongoing response at days 141 and 308.

Back to article page